Skip to main navigation
Skip to main content
Skip to Footer
US
Sandoz Site Directory
Home
Our Work
What We Do
Disease Areas
Quality Generics
Biosimilars
Partnerships and Collaborations
Access to Healthcare
About Us
Who We Are
Corporate Responsibility
Investor Information
Contact Us
Doing Business Responsibly
Patients & Customers
Report Side Effects
Product Safety Notices
Information for Customers
Products
Sandoz Patient Assistance
News
US Press Releases & News
Media Contacts
Publications
Careers
Job Search
Working at Sandoz US
Diversity & Inclusion
Search
All News
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Featured News
Media Releases
In the News
Filter By
2023
September
Featured News
/
Sep 08, 2023
FDA approves Tyruko® (natalizumab-sztn), the first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Read More
August
Featured News
/
Aug 28, 2023
Sandoz AG expands reach of adalimumab biosimilar in US through commercialization agreement with Cordavis
Read More
Media Release
/
Aug 24, 2023
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Read More
July
Featured News
/
Jul 10, 2023
Hyrimoz® (adalimumab-adaz) high-concentration formulation now available in the US
Read More
Media Release
/
Jul 01, 2023
Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space
Read More
June
Media Release
/
Jun 16, 2023
Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines
Read More
Media Release
/
Jun 16, 2023
Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines
Read More
March
Media Release
/
Mar 21, 2023
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Biosimilar Hyrimoz
®
(adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine
Humira
®
*
With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulation
Sandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition
Read More
Featured News
/
Mar 20, 2023
Engaging with Critical Stakeholders at the 2023 National Health Council’s Leadership Conference
Read More
February
Media Release
/
Feb 07, 2023
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
Read More
Search Results Navigation
Current page
1
of 5
Page
2
of 5
Page
3
of 5
Page
4
of 5
Page
5
of 5
…
Next page
next ›
Last page
last »
Twitter
Tweet
Facebook
Share
Share
Twitter
Facebook
LinkedIn
Email
Jump to Comments
Print
Save
You are here
Home
›
News
›
